

FOR IMMEDIATE RELEASE

March 30, 2016

Eisai Co., Ltd.
Ajinomoto Co., Inc.

9-65=7C'Z@B "5B8'5>-BCAHC'7C'Z-B7"

specialized research and development as well as a unique product lineup, and provide a wide range of solutions to patients and their families.

<Corporate Vision>

1. Specializing in gastrointestinal diseases such as inflammatory bowel disease (IBD), we will strive to address unmet medical needs through advanced research and development as well as focusing management resources on marketing activities from the patients' perspective.
2. All employees will conduct business activities that adhere strictly to all laws and ethics, and as a company, EA Pharma will aim to maximize social value to contribute to increasing corporate value for both the Eisai and Ajinomoto groups.

For reference

Product Lineup

Product name	Drug classification
AZULOXA [®] Tablets 15 mg, Granules 2.5%	Anti-gastric ulcer agent
ARGIMATE [®]	Anti-hyperammonemia agent
Argi-U [®] Injection / Granules	Urea cycle disorder agent
ES-POLYTAMIN [®] Granules	Essential amino acid formula
ELENTAL [®]	Elemental diet
ELENTAL [®] P	Elemental diet for neonate and infant
Enteronon [®] -R	Antibiotic-resistant lactic acid bacteria
Stronger Neo-Minophagen [®] C Injection 5 mL, 20 mL / P Injection 20 mL / Injection Syringe 20 mL, 40 mL	Liver disease / allergic disease treatment
Glycyron [®] Tablets	Liver disease / allergic disease treatment
GLUCAGON for Inj. 1 unit "ITO"	Synthetic glucagon
Selbex [®] Capsules 50 mg / Granules 10%	Gastritis / gastric ulcer treatment
Teleminsoft [®] Suppositories 2 mg,10mg	Bowel movement accelerating agent
Niflec [®]	Oral cleaning solution for intestine
Pariet [®] Tablets 5 mg, 10 mg, 20 mg	Proton pump inhibitor

ACTONEL [®] Tablets 17.5 mg [Licensee: Eisai Co., Ltd.]	Antihypertensive agent, Paget's disease agent
ATEDIO [®] Combination Tablets [Licensee: MOCHIDA PHARMACEUTICAL CO., LTD.]	Selective AT ₁ receptor blocker / Long-acting calcium channel blocker

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our *human health care* (